Article

FDA extends aflibercept review

The FDA has extended by 3 months its target date to complete a priority review of the biologics license application (BLA) of aflibercept injection for intravitreal use (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of neovascular age-related macular degeneration (AMD) to Nov. 18.

Tarrytown, NY-The FDA has extended by 3 months its target date to complete a priority review of the biologics license application (BLA) of aflibercept injection for intravitreal use (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of neovascular age-related macular degeneration (AMD) to Nov. 18.

The agency classified recent responses to questions regarding the chemistry, manufacturing, and controls section of the BLA as a major amendment to the application, according to the company. The new action date will give the agency additional time to review the submitted information.

Regeneron maintains exclusive rights to aflibercept injection in the United States, but the company is collaborating with Bayer HealthCare on the global development of the fusion protein for the treatment of neovascular AMD, central retinal vein occlusion, diabetic macular edema, and other eye diseases and disorders.

Bayer HealthCare will market aflibercept injection outside the United States, where the companies will share equally in the profits from any future sales of the fusion protein. In June, Bayer submitted an application to market the product for wet AMD in Europe.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.